Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand

Platinum (Pt) antineoplastic agents remain indispensable for the treatment of oncological disease. Pt-based drugs are mainly used in the therapy of ovarian cancer and non-small-cell lung carcinoma. A novel platinum-containing antineoplastic agent BP-C1 is a complex of diamminoplatinum with an oxygen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena Fedoros, Sergey Pigarev, Natalya Ivanenko, Megan Westbury, Nikolay Solovyev
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	protein binding free platinum anticancer drugs lignin equilibrium dialysis inductively coupled plasma mass spectrometry Technology T Engineering (General). Civil engineering (General) TA1-2040 Biology (General) QH301-705.5 Physics QC1-999 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/82ec82cf823c4f0fa8c4211cbed7a0b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82ec82cf823c4f0fa8c4211cbed7a0b5
record_format	dspace
spelling	oai:doaj.org-article:82ec82cf823c4f0fa8c4211cbed7a0b52021-11-25T16:42:52ZProtein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand10.3390/app1122110082076-3417https://doaj.org/article/82ec82cf823c4f0fa8c4211cbed7a0b52021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3417/11/22/11008https://doaj.org/toc/2076-3417Platinum (Pt) antineoplastic agents remain indispensable for the treatment of oncological disease. Pt-based drugs are mainly used in the therapy of ovarian cancer and non-small-cell lung carcinoma. A novel platinum-containing antineoplastic agent BP-C1 is a complex of diamminoplatinum with an oxygen-donor polymeric ligand of benzene-polycarboxylic acids, isolated from natural lignin. The aim of the study was to investigate ex vivo protein binding of BP-C1. Protein binding of BP-C1 was tested using equilibrium dialysis. Pooled blood plasma was used in the study. Control solutions contained the same dosages of BP-C1 in PBS (pH 7.2). Plasma and control solutions were submitted to equilibrium dialysis across a vertical 8 kDa cut-off membrane for 4 h at 37 °C under gentle shaking. Platinum was quantified in dialysis and retained fractions using inductively coupled plasma mass spectrometry after microwave digestion. The dialysis system was tested and validated; this showed no protein saturation with platinum. A medium degree of binding of platinum to macromolecular species of ca. 60% was observed. The study showed the maintenance of a high fraction of free BP-C1 in the bloodstream, facilitating its pharmacological activity.Elena FedorosSergey PigarevNatalya IvanenkoMegan WestburyNikolay SolovyevMDPI AGarticleprotein bindingfree platinumanticancer drugsligninequilibrium dialysisinductively coupled plasma mass spectrometryTechnologyTEngineering (General). Civil engineering (General)TA1-2040Biology (General)QH301-705.5PhysicsQC1-999ChemistryQD1-999ENApplied Sciences, Vol 11, Iss 11008, p 11008 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	protein binding free platinum anticancer drugs lignin equilibrium dialysis inductively coupled plasma mass spectrometry Technology T Engineering (General). Civil engineering (General) TA1-2040 Biology (General) QH301-705.5 Physics QC1-999 Chemistry QD1-999
spellingShingle	protein binding free platinum anticancer drugs lignin equilibrium dialysis inductively coupled plasma mass spectrometry Technology T Engineering (General). Civil engineering (General) TA1-2040 Biology (General) QH301-705.5 Physics QC1-999 Chemistry QD1-999 Elena Fedoros Sergey Pigarev Natalya Ivanenko Megan Westbury Nikolay Solovyev Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
description	Platinum (Pt) antineoplastic agents remain indispensable for the treatment of oncological disease. Pt-based drugs are mainly used in the therapy of ovarian cancer and non-small-cell lung carcinoma. A novel platinum-containing antineoplastic agent BP-C1 is a complex of diamminoplatinum with an oxygen-donor polymeric ligand of benzene-polycarboxylic acids, isolated from natural lignin. The aim of the study was to investigate ex vivo protein binding of BP-C1. Protein binding of BP-C1 was tested using equilibrium dialysis. Pooled blood plasma was used in the study. Control solutions contained the same dosages of BP-C1 in PBS (pH 7.2). Plasma and control solutions were submitted to equilibrium dialysis across a vertical 8 kDa cut-off membrane for 4 h at 37 °C under gentle shaking. Platinum was quantified in dialysis and retained fractions using inductively coupled plasma mass spectrometry after microwave digestion. The dialysis system was tested and validated; this showed no protein saturation with platinum. A medium degree of binding of platinum to macromolecular species of ca. 60% was observed. The study showed the maintenance of a high fraction of free BP-C1 in the bloodstream, facilitating its pharmacological activity.
format	article
author	Elena Fedoros Sergey Pigarev Natalya Ivanenko Megan Westbury Nikolay Solovyev
author_facet	Elena Fedoros Sergey Pigarev Natalya Ivanenko Megan Westbury Nikolay Solovyev
author_sort	Elena Fedoros
title	Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
title_short	Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
title_full	Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
title_fullStr	Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
title_full_unstemmed	Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
title_sort	protein binding of a novel platinum-based anticancer agent bp-c1 containing a lignin-derived polymeric ligand
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/82ec82cf823c4f0fa8c4211cbed7a0b5
work_keys_str_mv	AT elenafedoros proteinbindingofanovelplatinumbasedanticanceragentbpc1containingaligninderivedpolymericligand AT sergeypigarev proteinbindingofanovelplatinumbasedanticanceragentbpc1containingaligninderivedpolymericligand AT natalyaivanenko proteinbindingofanovelplatinumbasedanticanceragentbpc1containingaligninderivedpolymericligand AT meganwestbury proteinbindingofanovelplatinumbasedanticanceragentbpc1containingaligninderivedpolymericligand AT nikolaysolovyev proteinbindingofanovelplatinumbasedanticanceragentbpc1containingaligninderivedpolymericligand
_version_	1718413029402476544

Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand

Ejemplares similares